Wendy Wj de Leng

11PUBLICATIONS
100CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Craniofacial biologyMolecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 28, 2026
Molecular Features Associated with a High-Risk Clinical Course in Neuroblastomas Initially Diagnosed as Non-High-Risk.

Rixt S Bruinsma, Wendy W J de Leng, Marta F Fiocco

|Oct 01, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn

|Feb 05, 2025
Ameloblastic Fibro-Odontoma with an FGFR1 Mutation: A Case Report.

Oumaima Aouam, Nard G Janssen, Wendy W J de Leng

|Jan 31, 2025
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics.

Guy Froyen, Pieter-Jan Volders, Ellen Geerdens

|Jul 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Laurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia

|May 15, 2024
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.

Birgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen

Pageof 2

Frequent Collaborators

6 joint publications

Anne Ml Jansen

6 joint publications

Hans Gelderblom

5 joint publications

Vincent van der Noort

5 joint publications

Henk Mw Verheul